Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00507767 · ClinicalTrials.gov registry record · Phase 2
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00507767: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00507767 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00507767, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG dasatinib
- PROCEDURE laboratory biomarker analysis
- PROCEDURE pharmacological study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00507767
The ClinicalTrials.gov registry entry for NCT00507767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dasatinib is the first listed.
NCT00507767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00507767 about?
NCT00507767 is a clinical study titled "Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer". This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00507767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-07. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00507767?
The interventions under investigation include: dasatinib (DRUG), laboratory biomarker analysis (PROCEDURE), pharmacological study (PROCEDURE).
Who is sponsoring clinical trial NCT00507767?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.